An 81-year-old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5-month progression-free survival. Atez/Bev might exhibit efficacy for CHC patients.
Keywords: anti‐programmed death ligand‐1; hepatic resection; immune checkpoint inhibitor; liver cancer; vascular endothelial growth factor.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.